However, the impact of genetic variants in NKG2C and HLA-E on clinical outcomes of aggressive B-cell non-Hodgkin lymphoma patients (B-NHL) has not been clarified. The gene discussed is HLA-E; the disease is B-cell non-Hodgkin lymphoma.